Login / Register
0

ETV6/NTRK3 Fusion Gene t (12;15) Probe Reagent (Fluorescence in Situ Hybridization)

ETV6/NTRK3 Fusion Gene t (12;15) Probe Reagent (Fluorescence in Situ Hybridization)

Catalog Number:
ISH1136159CEL
Mfr. No.:
CF1078
Price:
Inquiry
  • Size:
    Quantity:
    Add to Cart:
    Add to Cart
      • Overview

        • Clinic Signification：
          1. Vitrakvi is the first FDA-approved oral TRK inhibitor to be marketed and also the first "broad-spectrum" anticancer drug that has nothing to do with tumor type. Targeted therapy for patients with NTRK gene (NTRK1/2/3) fusion, including: lung cancer, thyroid cancer, melanoma, gastrointestinal cancer, colon cancer, soft tissue sarcoma, salivary glands, infantile fibrosarcoma, appendix cancer, breast cancer, cholangiocarcinoma, pancreatic cancer etc.

          Please contact us at for specific academic pricing.

      • Properties
        • Categories
          FISH
          Other Properties
          Probe: ETV6/NTRK3

          * For research use only.

      • Applications
        • Application
          Fluorescent In Situ Hybridization

    We Also Recommend

    20q Deletion Detection Kit

    20q Deletion Detection Kit

    7q Deletion Detection Kit

    7q Deletion Detection Kit

    EGR1 Deletion Detection Kit

    EGR1 Deletion Detection Kit

    EVI Breakapart Detection Kit

    EVI Breakapart Detection Kit

    Note: If you don't receive our verification email, do the following:

    • Confirm that you entered your email address correctly.
    • Check if the email is in your spam or junk folder.
    • Or you may contact us at .
    • Products
    Amerigo Scientific
    Support
    Contact Us
    Copyright © Amerigo Scientific. All rights reserved.